Cambridge Cancer Genomics
AcquiredCCG.ai empowers clinicians to make personalised treatment strategies…
Cambridge, United Kingdom · Founded 2015 · $4.5M raised
- Total Funding
- $4.5M
- Last Round
- $4.5M Series ADec 2018
- Rounds
- 1
About
CCG.ai exist to ensure that each patient has the right drug, at the right time, to beat their cancer. We build the software to enable data-driven precision oncology and systematically develop data-driven biomarkers indicative of treatment response. We believe that increasing amounts of clinical and genomic data have the potential to transform cancer treatment, and enable oncologists to make smarter decisions about which drug to use in which circumstance. We are expanding our team in Cambridge, UK, offering a fantastic opportunity for dedicated individuals who are comfortable in a high-work high-reward environment, and who are enthusiastic for a dynamic and varied role. We are looking for people who fit well into our team and company culture, and who like to overcome challenges and drive the business forward. In exchange, we offer a competitive salary with performance related bonuses and stock options, alongside excellent career development opportunities in a fast-growing start-up with a chance to truly impact how cancer is treated. To apply, please send your CV to info@ccg.ai
Summary
Cambridge Cancer Genomics is a Genomics company based in Cambridge, United Kingdom, founded in 2015. It has raised $4.5M in total across 1 round, most recently a $4.5M Series A round in Dec 2018. Investors include Refactor Capital, Romulus Capital and AME Cloud Ventures.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Dec 2018
Investors
Similar Companies
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...

Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...
Novel DNA sequencing architecture to scale the ultra low cost whole genome
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Biotechnology company developing multi-cancer early detection blood tests using high-intensity ge...
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...